Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252045 | 0.82 | APP (0.48) | APPGRM5NPC1RAB9ACYP1A2 | |
| SCHEMBL28337842 | 0.80 | MEN1 (0.42) | GRM5NPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6254610 | 0.80 | APP (0.46) | APPGRM5NPC1RAB9ACYP1A2 | |
| SCHEMBL2822012 | 0.78 | APP (0.44) | APPNPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL2185739 | 0.78 | GRM5 (0.40) | APPGRM5CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5687827 | 0.78 | P2RY6 (0.32) | — | |
| SCHEMBL6562619 | 0.77 | APP (0.42) | APPGRM5NPC1RAB9ACYP1A2 | |
| SCHEMBL6564071 | 0.75 | GRM5 (0.42) | APPGRM5NPC1RAB9ACYP1A2 | |
| SCHEMBL15756940 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP3A4ALDH1A1ALOX15 | |
| SCHEMBL734904 | 0.74 | DHFR (0.41) | GRM5NPSR1ALDH1A1TP53KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022248067-A1 | SILIRENE-FUNCTIONALIZED COMPOUNDS AND MIXTURES THEREOF FOR PREPARING SILOXANES AND CONFERRING ADHESION-PROMOTING PROPERTIES ON THEM | WACKER CHEMIE AG (DE) | 2022-12-01 | — | — | WO | disclosed |
| EP-3642890-A1 | NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE | Robert Bosch GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3628103-A1 | NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE, AND METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE | Robert Bosch GmbH (DE) | 2020-04-01 | — | — | EP | disclosed |
| WO-2018224286-A1 | NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE, AND METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE | Lithium Energy and Power GmbH & Co. KG (DE) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018224279-A1 | NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE | Lithium Energy and Power GmbH & Co. KG (DE) | 2018-12-13 | — | — | WO | disclosed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | disclosed |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-26 | — | — | US | disclosed |
| US-8466167-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2013-06-18 | — | — | US | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7358250-B2 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1791845-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006130160-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | disclosed |
| US-4841084-A | New hexacoordinate silicon complexes, the process for their preparation and their application | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-06-20 | — | — | US | disclosed |
| EP-0191259-B1 | HEXACOORDINATED SILICON COMPLEXES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1989-05-24 | — | — | EP | disclosed |
| EP-0191259-A1 | Hexacoordinated silicon complexes, process for their preparation and their use | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | APP 1406/4885GRM5 1159/4885NPC1 4177/4885 |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | APP 2848/4885GRM5 56/4885NPC1 761/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | APP 2848/4885GRM5 56/4885NPC1 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.